[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369610-105":59,"doc-detail-369610-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","discovery-of-drugs-targeting-mutant-p53-and-progress-in-nano-enabled-therapeutic-strategy-for-p53-mutated-cancers","Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers","","Mutations in the p53 gene are common across cancers, driving decades of efforts to restore p53 function as a treatment strategy. Despite this, few programs have reached late-stage clinical trials, and no p53-targeted therapies have been approved in the USA or Europe. The review explains the translational barriers tied to p53’s nuclear transcription-factor nature and “undruggable” perception, then surveys emerging small-molecule and mutation-specific approaches, depletion strategies, genetic therapies, and nanotechnology-enabled delivery while noting persistent clinical challenges.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/discovery-of-drugs-targeting-mutant-p53-and-progress-in-nano-enabled-therapeutic-strategy-for-p53-mutated-cancers/369610/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/discovery-of-drugs-targeting-mutant-p53-and-progress-in-nano-enabled-therapeutic-strategy-for-p53-mutated-cancers/369610.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is mutant p53 considered difficult to target with conventional drugs?","Question",{"text":112,"@type":113},"p53 is primarily a nuclear transcription factor and lacks typical drug-target characteristics, so it has historically been viewed as “undruggable.” Translational challenges persist even as new strategies emerge.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What therapeutic directions are covered for p53-mutant cancers?",{"text":117,"@type":113},"The review discusses small molecules that restore mutant p53 tumor-suppressive activity, mutation-specific drug design, strategies to deplete mutant p53, and approaches exploiting vulnerabilities linked to p53 expression. It also addresses genetic therapy strategies.",{"name":119,"@type":110,"acceptedAnswer":120},"How does nanotechnology contribute to p53-based therapies?",{"text":121,"@type":113},"Nanotechnology-enabled strategies can support p53-targeted treatment modalities by improving delivery and enabling therapy options specifically highlighted in the review. The review also emphasizes remaining obstacles in clinical development.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369610,1790520775,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review  \nDiscovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers  \nNa Zhang 1,†, Zhiyuan Jing 1,†, Jie Song 1, Qiyue Liang 1, Yuxue Xu 1, Zhaowei Xu 1, Longping Wen 2, * and Pengfei Wei 1, *  \nAcademic Editors: Annarita Falanga and Dirk Geerts  \nReceived: 21 March 2025  \nRevised: 14 May 2025  \nAccepted: 23 May 2025  \nPublished: 26 May 2025  \nCitation: Zhang, N.; Jing, Z.; Song, J.; Liang, Q.; Xu, Y.; Xu, Z.; Wen, L.; Wei, P. Discovery of Drugs Targeting Mutant p53 and Progress in  \nNano-Enabled Therapeutic Strategy for p53-Mutated Cancers. Biomolecules 2025, 15, 763. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/biom15060763](10.3390/biom15060763)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, School of Pharmacy, Binzhou Medical University, Yantai 264003, China; [zhangna20@bzmc.edu.cn](zhangna20@bzmc.edu.cn) (N.Z.); [2022082600@stu.bzmc.edu.cn](2022082600@stu.bzmc.edu.cn) (Z.J.); [2023081004@stu.bzmc.edu.cn](2023081004@stu.bzmc.edu.cn) (J.S.); [2023081039@stu.bzmc.edu.cn](2023081039@stu.bzmc.edu.cn) (Q.L.); [xuyuxue@bzmc.edu.cn](xuyuxue@bzmc.edu.cn) (Y.X.); [zhaoweixv@bzmc.edu.cn](zhaoweixv@bzmc.edu.cn) (Z.X.)  \n2 Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China  \n* Correspondence: [lpwen@ustc.edu.cn](lpwen@ustc.edu.cn) (L.W.); [pfwei@bzmc.edu.cn](pfwei@bzmc.edu.cn) (P.W.)† These authors contributed equally to this work.  \nAbstract: Mutations in the p53 gene are frequently observed in various cancers, prompting the initiation of efforts to restore p53 function as a therapeutic approach several decades ago. Nevertheless, only a limited number of drug development initiatives have progressed to late-stage clinical trials, and to date, no p53-targeted therapies have received approval in the USA or Europe. This situation can be attributed primarily to the characteristics of p53 as a nuclear transcription factor, which lacks the conventional features associated with drug targets and has historically been considered “undruggable”. In recent years, however, several promising strategies have emerged, including the enhanced iterations of previous approaches and novel techniques aimed at targeting proteins that have traditionally been considered undruggable. There is a growing interest in small molecules that can restore the tumor-suppressive functions of mutant p53 proteins, and the development of drugs specifically designed for particular p53 mutation types is currently underway. Other approaches aim to deplete mutant p53 or exploit vulnerabilities associated with its expression. Additionally, genetic therapy strategy and approaches have rekindled interest. Advancesin mutant p53 biology, compound mechanisms, treatment modalities, and nanotechnology have opened up new avenues for p53-based therapies. However, significant challenges remain in clinical development. This review reassesses the progress in targeting p53-mutant cancers, discusses the obstacles in translating these approaches into effective therapies, and highlights p53-based therapies via nanotechnology.  \nKeywords: mutant p53; mutant p53 reactivation; protein stability; nanodelivery  \n1. Introduction  \nThe p53 gene, identified in 1979 [1], is a crucial tumor suppressor with diverse functions in cancer biology. Initially mischaracterized as interacting with viral proteins, it was later recognized for its role in inhibiting tumor growth. Early research on p53 involved synthesizing cDNA from tumor cell mRNA, initially suggesting","cbCaidahxafldgtF","https://ap.wps.com/l/cbCaidahxafldgtF","pdf",5345237,36,"English","# Introduction\n## p53 biology and tumor-suppressive functions\n## MDM2 regulation of wild-type p53\n# Therapeutic rationale for mutant p53 targeting\n## Drug development status and translational obstacles\n## Emerging strategies and nanotechnology approaches","[{\"question\":\"Why is mutant p53 considered difficult to target with conventional drugs?\",\"answer\":\"p53 is primarily a nuclear transcription factor and lacks typical drug-target characteristics, so it has historically been viewed as “undruggable.” Translational challenges persist even as new strategies emerge.\"},{\"question\":\"What therapeutic directions are covered for p53-mutant cancers?\",\"answer\":\"The review discusses small molecules that restore mutant p53 tumor-suppressive activity, mutation-specific drug design, strategies to deplete mutant p53, and approaches exploiting vulnerabilities linked to p53 expression. It also addresses genetic therapy strategies.\"},{\"question\":\"How does nanotechnology contribute to p53-based therapies?\",\"answer\":\"Nanotechnology-enabled strategies can support p53-targeted treatment modalities by improving delivery and enabling therapy options specifically highlighted in the review. The review also emphasizes remaining obstacles in clinical development.\"}]","Discovery of Drugs Targeting Mutant p53 and Progress in Nano-Enabled Therapeutic Strategy for p53-Mutated Cancers | PDF",1790183672,91,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87f3e3a4d933a8c406cd49487e0e1a27.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1a1bc970a4ff2ec7ad48d34a468b24e.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ed02acf6f84153c90e87be71ff48c11.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e079d2e4a482c4b6bc32faf811f21614.webp",980,1385]